Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

eribulin

- PMLiVE

World Cancer Day – CoppaFeel! and NHS NELCA urge young people to ‘Check In’

The co-designed campaign aims to challenge misconceptions surrounding breast cancer

- PMLiVE

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

About 15,000 people in England are living with the inherited blood disorder

- PMLiVE

UK access pathway launched to get new medicines to patients in ‘shortest time possible’

The ILAP offers drug developers a single platform to collaborate with the MHRA and HTA bodies

- PMLiVE

Roche shares positive overall survival results for Itovebi in advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

- PMLiVE

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe

The questionnaire gathered insights from 7,750 adults across five countries

- PMLiVE

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

More than 49,000 people are diagnosed with lung cancer in the UK each year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

Biogen Idec building

Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

- PMLiVE

Eli Lilly to acquire Scorpion’s solid tumour programme in deal worth $2.5bn

STX-478 is in phase 1/2 development for breast cancer and other advanced solid tumours

Bayer symbol

Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links